Axel Le Cesne Selected Research

Ifosfamide

1/2020	Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
1/2020	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
1/2018	Making the Best of Available Options for Optimal Sarcoma Treatment.
4/2017	Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study.
7/2015	Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.
6/2013	13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
10/2012	Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
2/2012	Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy.
3/2011	Treating soft tissue sarcomas with adjuvant chemotherapy.
1/2010	Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Axel Le Cesne Research Topics

Disease

92	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 08/2005
71	Neoplasms (Cancer) 01/2022 - 01/2003
31	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 04/2022 - 08/2004
19	Leiomyosarcoma 11/2020 - 11/2005
17	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2004
14	Disease Progression 01/2021 - 06/2012
11	Liposarcoma 01/2022 - 07/2007
10	Fatigue 01/2022 - 09/2006
9	Aggressive Fibromatosis (Desmoid) 01/2021 - 06/2003
9	Neutropenia 01/2019 - 07/2007
7	Nausea 01/2022 - 09/2006
7	Hemangiosarcoma (Angiosarcoma) 01/2022 - 01/2012
7	Synovial Sarcoma (Synovioma) 01/2018 - 04/2008
5	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 08/2012
5	Hypertension (High Blood Pressure) 01/2020 - 07/2009
3	Fibroma (Fibromatosis) 01/2021 - 12/2009
3	Myxoid Liposarcoma 01/2019 - 07/2007
3	Genetic Translocation (Chromosomal Translocation) 01/2019 - 07/2007
3	Thrombocytopenia (Thrombopenia) 04/2015 - 10/2008
3	Febrile Neutropenia 04/2015 - 07/2007
2	Cardiotoxicity 01/2020 - 04/2007
2	Lymphopenia (Lymphocytopenia) 01/2020 - 07/2009
2	Pain (Aches) 01/2019 - 01/2017
2	Alveolar Soft Part Sarcoma 01/2019 - 01/2018
2	Anorexia 01/2018 - 02/2013
2	Desmoplastic Small Round Cell Tumor 01/2017 - 04/2015
2	Chordoma 01/2017 - 01/2009
2	Epithelioid Hemangioendothelioma 09/2014 - 07/2013
2	Exanthema (Rash) 07/2013 - 09/2006
2	Alopecia (Baldness) 06/2013 - 03/2012
2	Breast Neoplasms (Breast Cancer) 08/2011 - 07/2009
1	Rupture 01/2020
1	Vitelliform Macular Dystrophy 01/2020
1	Carcinogenesis 12/2019
1	Osteonecrosis (Kienbock's Disease) 12/2019
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2019

Drug/Important Bio-Agent (IBA)

40	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 01/2003
24	TrabectedinIBA 12/2020 - 07/2007
19	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 08/2006
14	Ifosfamide FDA LinkGeneric 01/2020 - 08/2006
11	Tyrosine Kinase InhibitorsIBA 04/2022 - 02/2009
11	Phosphotransferases (Kinase)IBA 01/2021 - 07/2005
9	Pharmaceutical PreparationsIBA 01/2022 - 01/2009
7	AnthracyclinesIBA 07/2021 - 09/2009
7	pazopanib FDA Link 01/2020 - 07/2009
6	regorafenibIBA 12/2020 - 01/2013
5	Biological ProductsIBA 01/2022 - 11/2005
5	Biomarkers (Surrogate Marker)IBA 12/2020 - 06/2012
5	Proteins (Proteins, Gene)FDA Link 12/2019 - 11/2005
5	DNA (Deoxyribonucleic Acid)IBA 12/2019 - 01/2007
5	Alanine Transaminase (SGPT)IBA 05/2015 - 10/2008
5	Sunitinib (Sutent)FDA Link 11/2014 - 04/2010
5	Sorafenib (BAY 43-9006)FDA Link 11/2014 - 04/2010
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2013 - 05/2007
3	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 02/2012
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 09/2014
3	Gemcitabine FDA Link 01/2020 - 08/2006
3	Dacarbazine (DIC)FDA LinkGeneric 01/2020 - 04/2016
3	Messenger RNA (mRNA)IBA 01/2019 - 08/2011
3	Docetaxel (Taxotere)FDA Link 01/2019 - 03/2004
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2017 - 08/2004
3	Cytotoxins (Cytolysins)IBA 01/2012 - 08/2006
2	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021 - 12/2020
2	Transaminases (Aminotransferases)IBA 01/2020 - 06/2012
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 02/2012
2	RNA (Ribonucleic Acid)IBA 12/2019 - 01/2008
2	Oncogene Proteins (Oncogene Protein)IBA 01/2019 - 11/2012
2	Paclitaxel (Taxol)FDA LinkGeneric 10/2018 - 09/2015
2	Bevacizumab (Avastin)FDA Link 10/2018 - 09/2015
2	nilotinib FDA Link 01/2018 - 05/2015
2	eribulin FDA Link 04/2016 - 10/2011
2	Codon (Codons)IBA 10/2013 - 07/2004
2	ridaforolimusIBA 07/2013 - 08/2012
2	EnzymesIBA 02/2013 - 07/2009
2	Angiogenesis InhibitorsIBA 05/2012 - 07/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2012 - 12/2009
2	Melphalan (Alkeran)FDA LinkGeneric 02/2012 - 12/2009
2	Gefitinib (Iressa)FDA Link 04/2008 - 02/2005
1	selinexorIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	Anaplastic Lymphoma KinaseIBA 11/2020
1	Cyclin-Dependent Kinase 4IBA 09/2020
1	olaratumabIBA 01/2020
1	Denosumab FDA Link 12/2019
1	Poly (ADP-Ribose) Polymerase-1IBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Vinblastine (Vinblastine Sulfate)FDA Link 01/2019
1	ontuxizumabIBA 01/2019

Therapy/Procedure

41	Therapeutics 01/2022 - 11/2004
41	Drug Therapy (Chemotherapy) 01/2022 - 01/2003
11	Radiotherapy 01/2022 - 02/2006
6	Adjuvant Chemotherapy 01/2022 - 11/2006
4	Neoadjuvant Therapy 09/2021 - 11/2006
4	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 10/2011
3	Aftercare (After-Treatment) 06/2015 - 04/2005
2	Brachytherapy 01/2022 - 02/2006
2	Immunotherapy 01/2018 - 05/2007
1	Precision Medicine 07/2021
1	Conformal Radiotherapy 07/2021
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 07/2021